ClinicalTrials.gg
Drug

Becotatug vedotin clinical trials

Also written MRG003.

studies test it
62
open now
55
in phase 3
6
first study started
2018

How each study uses becotatug vedotin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the becotatug vedotin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Becotatug Vedotin
23
Becotatug Vedotin (MRG003)
8
MRG003 (Becotatug Vedotin)
2

Development codes

MRG003
17

In one entry with another drug

Given together, or one or the other

Becotatug Vedotin (recombinant humanized anti-EGFR mAb-MMAE conjugate) combined with Pucotenlimab (recombinant humanized anti-PD-1 mAb)
2
MRG003+Pucotenlimab
2
Becotatug Vedotin and Pucotenlimab
2

Studies by the year they started

61 studies that test it; most in 2026 (50); 1 more planned to start later

Studies that test becotatug vedotin, by start year
YearStudies
20181
20214
20221
20232
20241
20252
202650

Who runs them

Industry 10 · Other 52

Lepu Biopharma Co., Ltd. (10) · Sun Yat-sen University (10) · Fudan University (7) · Tianjin Medical University Cancer Institute and Hospital (3) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (2) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (2) · West China Hospital (2) · Jiyan Liu (2)

Often tested with

Tested in the same studies.

Pucotenlimab (21) · Immune checkpoint inhibitors (3) · Ado-Trastuzumab Emtansine (1) · Trastuzumab deruxtecan (1) · Datopotamab deruxtecan (1) · Sacituzumab govitecan (1) · Enfortumab vedotin (1) · Izalontamab brengitecan (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 15

Studies that test becotatug vedotin.

Studies

Open first, then newest update. How each study uses becotatug vedotin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 62

See all 62 studies that test becotatug vedotin →

Given beside what is tested · 2 — becotatug vedotin is usual care or a partner of the new treatment

Codes

What other systems call becotatug vedotin · ClinicalTrials.gg INT018246

  • UNII (FDA) VHA6L8H5FMBECOTATUG VEDOTINOne source FDA
  • NCI Thesaurus C180585Becotatug VedotinOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.